Xog cusub oo ku saabsan daawaynta ka hortagga fayraska ee Cagaarshowga B iyo C

Sayniska Gilecaad ayaa maanta ku dhawaaqay xog laga helay daraasado badan oo muujinaya faa'iidada kiliinikada iyo kala duwanaanta daawaynta cagaarshowga, iyo sidoo kale ka go'naanta joogtada ah ee Gilecaad ee cilmi-baarista beerka si loo horumariyo ciribtirka cagaarshowga fayraska ee Aasiya. Xogta waxaa lagu soo bandhigay Shirweynaha 31aad ee Ururka Aasiya Baasifigga ee Barashada Beerka (APASL 2022), Maarso 30 - Abriil 3, 2022 ee Seoul, South Korea.    

"Xogta kiliinikada ee daraasadaheena waxay xoojineysaa waxtarka iyo badbaadada si wanaagsan loo aasaasay ee daaweyntayada iyo faa'iidada kiliinikada ee suurtagalka ah ee dadka qaba cagaarshow B iyo C. Xogta dhiirigelinta ah waxay sii kordhin kartaa taageerada bixiyeyaasha daryeelka caafimaadka si ay u sameeyaan doorashada daaweynta habboon ee bukaannada cagaarshow. Aasiya.” ayuu yiri Betty Chiang, Madaxweyne ku xigeenka Arrimaha Caafimaadka, Caalamiga ah, Sayniska Gilecaad.

Xogta laga helay saddex Tenofovir (TFV) - daraasado ku salaysan daawaynta cagaarshowga B (HBV) ee lagu soo bandhigay shirka ayaa muujisay in bilawga daaweynta bukaanno yar oo halis hoose u ah kansarka hepatocellular (HCC) ay u gudbeen khatar sare, halka qaar badan oo dhexdhexaad ah ama sare ah. -Bukaannada halista ku jira ayaa kor u kacay ilaa ay hoos u dhigaan halista HCC daawaynta TFV ee muddada dheer ka dib.  

Xogta laga helay daraasadda Wajiga 2 ee TFV disoproxil fumarate (TDF) vs. TDF/emtricitabine (FTC) ee bukaannada difaaca u adkaysta (IT) iyo laba daraasadood oo 3 ah, marka la barbardhigo tenofovir alafenamide (TAF) vs. TDF ee difaaca-firfircoon (IA) ) Bukaannada ayaa loo isticmaalay si ay u dhaliyaan buundooyinka halista HCC iyadoo la adeegsanayo wax laga beddelay PAGE-B (mPAGE-B), qalab lagu saadaaliyo khatarta 5-sano ee HCC (khatarta hoose [0-≤8], khatar dhexdhexaad ah [9-12], iyo khatar sare [≥13]). 

126 ka mid ah bukaannada IT-ga, 106 (84%), 19 (15%) iyo 1 (0.8%) waxay ahaayeen khatar hoose, dhexdhexaad, ama sare, siday u kala horreeyaan. Usbuuca 192, badidoodu si cad ayaanan isbeddelin ama u hagaagin. Ma jiro bukaan IT soo maray HCC. Bukaannada 1,631 IA (1,092 TAF; 539 TDF-> TAF), 901 (55%), 588 (36%), iyo 142 (9%) waxay ahaayeen kuwo hoose, dhexdhexaad ah, ama khatar sare leh, siday u kala horreeyaan. Usbuuca 240, badidoodu isma bedelin ama way fiicnaadeen; kaliya 22 (2%) bukaan ayaa u wareegay khatar sare. Guud ahaan, 22 kiis oo HCC ah ayaa la sameeyay (0.2%, 1.2%, iyo 9.2% ee kooxaha khatarta hoose, dhexdhexaadka ah, iyo heerka sare).

Xog dheeraad ah oo lagu soo bandhigay shirka ayaa bixisa qiimaynta lafaha iyo kelyaha ee badbaadada TAF ee barnaamijka horumarinta kiliinikada ee Gilecaad ee TAF HBV. Xogta laga helay 1,911 bukaan oo lagu daweeyay TAF ama TDF ayaa la falanqeeyay waxaana lagu falanqeeyay noocyo badan oo bukaanno HBV ah, oo ay ku jiraan kuwa khatarta sare ugu jira lafaha ku xiran TDF iyo/ama sunta kelyaha. Lafaha iyo kelyaha oo xasiloon ama la hagaajiyay ayaa lagu arkay daawaynta TAF marka la barbar dhigo daawaynta TDF.

Cagaarshowga C, daraasadda wajiga 3b ee eegaysa daawaynta-naïve iyo daawaynta waayo-aragnimada cagaarshow C (CHC) ee bukaannada Kuuriya waxay muujisay in daaweynta sofosbuvir / velpatasvir iyo sofosbuvir / velpatasvir / voxilaprevir ay heleen jawaab celin fayras oo joogto ah oo aan lahayn daawaynta virologic. Dhacdooyin xunxun oo halis ah oo fashilma ama daawaynta la xidhiidha. Daraasad kale oo lagu qiimeynayo isdhexgalka daroogada-daroogada (DDI) ee bukaannada CHC ee Kuuriya oo isticmaalaya fayraska tooska ah ee tooska ah ee la heli karo, sofosbuvir / velpatasvir waxay muujisay muuqaal wanaagsan oo DDI ah inkastoo heerarka sare ee isku-dhafka iyo majaajilada ka mid ah isbeddellada gabowga ee dadweynaha CHC ee Kuuriya.